Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Non-Checkpoint Immunotherapies

Abstract B069: The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC

Gábor Tóth, Árpád Szöőr, László Simon, Yosef Yarden, János Szöllősi and György Vereb
Gábor Tóth
1University of Debrecen, Debrecen, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Árpád Szöőr
1University of Debrecen, Debrecen, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
László Simon
1University of Debrecen, Debrecen, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yosef Yarden
2Weizmann Institute of Science, Rehovot, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
János Szöllősi
1University of Debrecen, Debrecen, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
György Vereb
1University of Debrecen, Debrecen, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6066.IMM2016-B069 Published November 2016
  • Article
  • Info & Metrics
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: November 2016 to January 2021

AbstractFull-text HTMLPDF
Total38100

Cited By

Article Information

Volume 4, Issue 11 Supplement, pp. B069

DOI 
https://doi.org/10.1158/2326-6066.IMM2016-B069

Published By 
American Association for Cancer Research
Print ISSN 
2326-6066
Online ISSN 
2326-6074

Copyright & Usage 
©2016 American Association for Cancer Research.

Author Information

  1. Gábor Tóth1,
  2. Árpád Szöőr1,
  3. László Simon1,
  4. Yosef Yarden2,
  5. János Szöllősi1, and
  6. György Vereb1
  1. 1University of Debrecen, Debrecen, Hungary;
  2. 2Weizmann Institute of Science, Rehovot, Israel.
Previous
Back to top
Cancer Immunology Research: 4 (11 Supplement)
November 2016
Volume 4, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract B069: The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract B069: The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC
Gábor Tóth, Árpád Szöőr, László Simon, Yosef Yarden, János Szöllősi and György Vereb
Cancer Immunol Res November 1 2016 (4) (11 Supplement) B069; DOI: 10.1158/2326-6066.IMM2016-B069

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract B069: The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC
Gábor Tóth, Árpád Szöőr, László Simon, Yosef Yarden, János Szöllősi and György Vereb
Cancer Immunol Res November 1 2016 (4) (11 Supplement) B069; DOI: 10.1158/2326-6066.IMM2016-B069
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Non-Checkpoint Immunotherapies

  • Abstract IA24: New frontiers in oncolytic virus therapy
  • Abstract PR10: Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors
  • Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions
Show more Non-Checkpoint Immunotherapies

Non-Checkpoint Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract IA24: New frontiers in oncolytic virus therapy
  • Abstract PR10: Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors
  • Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions
Show more Non-Checkpoint Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement